# A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure

> **NCT02914665** · PHASE2 · COMPLETED · sponsor: **Stealth BioTherapeutics Inc.** · enrollment: 308 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** elamipretide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02914665
- **Lead sponsor:** Stealth BioTherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-20
- **Primary completion:** 2017-11-27
- **Final completion:** 2017-11-27
- **Target enrollment:** 308 (ACTUAL)
- **Last updated:** 2020-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02914665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02914665, "A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02914665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*